Pioneering Next Generation HLA Directed Engagers to Achieve High Precision, Tumor Agnostic Targeting of Solid Tumors
Time: 11:45 am
day: Day 2
Details:
- Exploiting tumor exclusive mutations as therapeutic targets to deliver off the shelf, precision T cell engagers
- Leveraging tumor specificity to enhance T cell activation and expand the therapeutic window in solid tumors·
- Catalyzing anti-tumor activity and counteracting immune resistance with novel HLA redirecting engager combination approaches
